Compare WETH & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WETH | LPCN |
|---|---|---|
| Founded | 1992 | 1997 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.9M | 18.7M |
| IPO Year | 2020 | 2011 |
| Metric | WETH | LPCN |
|---|---|---|
| Price | $0.81 | $1.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 78.0K | ★ 265.0K |
| Earning Date | 11-20-2026 | 11-05-2026 |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | ★ 15.38 | N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $45,136,818.00 | $1,976,677.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.02 |
| P/E Ratio | $1.63 | ★ N/A |
| Revenue Growth | ★ 6.76 | N/A |
| 52 Week Low | $0.72 | $1.36 |
| 52 Week High | $2.97 | $12.37 |
| Indicator | WETH | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 37.37 | 46.80 |
| Support Level | N/A | $1.36 |
| Resistance Level | $1.03 | $2.50 |
| Average True Range (ATR) | 0.09 | 0.10 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 32.37 | 63.16 |
Wetouch Technology Inc is a business of research and development, manufacturing, and distribution of touchscreen displays to customers both in the PRC and overseas. The touchscreen products, which are manufactured by the Company, are mainly for use in financial terminals, automotive, Point of Sales, gaming, lottery, medical, Human-Machine Interface (HMI), and other specialized industries. The company sells touchscreen products both domestically in China and internationally, covering areas in Mainland China, including but not limited to the eastern, southern, northern, and southwest regions of Mainland China, Taiwan, South Korea, Germany, and other countries.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.